Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Survey Underscores Label Communication Challenges

This article was originally published in The Tan Sheet

Executive Summary

An Edelman survey shows high consumer regard for OTC safety, efficacy and value, but finds that 24% of the 1,035 consumers surveyed have taken more than the indicated dosage of an OTC medicine to “more effectively treat their symptoms.”

You may also be interested in...



Online Portals: ‘Critical’ Doors To Boost Consumer OTC Literacy, Drive Sales

OTC firms should use online portals to provide details on OTC products and health conditions they treat, says health care services consultant Tim Covington. I\information currently available online is fragmented and fails to communicate the financial benefit of OTCs over unnecessary doctor’s visits, he says.

Online Portals: ‘Critical’ Doors To Boost Consumer OTC Literacy, Drive Sales

OTC firms should use online portals to provide details on OTC products and health conditions they treat, says health care services consultant Tim Covington. I\information currently available online is fragmented and fails to communicate the financial benefit of OTCs over unnecessary doctor’s visits, he says.

Pediatric Acetaminophen Panel Debates Execution Of Dosing Changes

Pediatric OTC acetaminophen product labels should include directions for children under 2 years and as young as 6 months and instructions for dosing by weight, a panel of advisors told FDA.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106235

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel